Previous 10 | Next 10 |
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a co...
2023-05-12 08:48:10 ET Summary AXNX reported impressive 1Q23 earnings with revenue of $70.7 million, representing a remarkable 46% year-on-year growth. The success of Axonics' F15 and Bulkamid products played a significant role in driving their strong performance. AXNX raised ...
2023-05-10 09:41:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Small Cap Fund® (the Fund) was up 9.44% (Institutional Shares) in the first...
2023-05-09 13:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Discovery Fund® (the Fund) was up 11.20% compared...
2023-05-04 06:22:39 ET Summary Axonics is under pressure after Q1 results came in solid but guidance didn't increase as much as hoped. The company has 2 solid products and the medical technology space has performed well recently. AXNX is a volatile small cap but the recent wea...
2023-05-01 21:36:06 ET Axonics, Inc. (AXNX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron...
2023-05-01 17:08:29 ET Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating expenses were $66.9 million in 1Q23 an...
Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment o...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities Healthcare Conference ...
2023-04-24 06:22:01 ET Axonics ( NASDAQ: AXNX ) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian from Intermed Labs for undisclosed terms. SNM is a...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
2024-06-19 23:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 07:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...